By PPN News Staff
The 0.1-mg epinephrine injection (AUVI-q, kaléo) will be available nationwide by prescription beginning May 1.
The product is indicated for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and toddlers weighing 16.5 to 33 pounds. Featuring a shorter needle length and lower dose of epinephrine than other FDA-approved epinephrine auto-injectors (EAIs), AUVI-q 0.1 mg is the first and only FDA-approved EAI designed for this patient